Last reviewed · How we verify
Pegylated Interferon alpha-2a
Pegylated Interferon alpha-2a is a Interferon alpha Small molecule drug developed by ANRS, Emerging Infectious Diseases. It is currently FDA-approved for Chronic hepatitis C, Chronic hepatitis B, Certain malignancies (melanoma, renal cell carcinoma). Also known as: Pegasys, Pegasys®, Roche, Peg-INF.
Pegylated interferon alpha-2a activates innate immune responses by binding to interferon-alpha receptors on immune cells, enhancing antiviral and antiproliferative activity.
Pegylated interferon alpha-2a activates innate immune responses by binding to interferon-alpha receptors on immune cells, enhancing antiviral and antiproliferative activity. Used for Chronic hepatitis C, Chronic hepatitis B, Certain malignancies (melanoma, renal cell carcinoma).
At a glance
| Generic name | Pegylated Interferon alpha-2a |
|---|---|
| Also known as | Pegasys, Pegasys®, Roche, Peg-INF |
| Sponsor | ANRS, Emerging Infectious Diseases |
| Drug class | Interferon alpha |
| Target | Interferon-alpha receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Virology, Oncology |
| Phase | FDA-approved |
Mechanism of action
Interferon alpha-2a is a cytokine that binds to type I interferon receptors (IFNAR1/IFNAR2) on cell surfaces, triggering JAK-STAT signaling pathways that upregulate antiviral genes and enhance natural killer cell and macrophage activity. Pegylation extends the drug's half-life by reducing renal clearance and increasing molecular size, allowing for less frequent dosing while maintaining therapeutic efficacy. This mechanism makes it effective against viral infections and certain malignancies.
Approved indications
- Chronic hepatitis C
- Chronic hepatitis B
- Certain malignancies (melanoma, renal cell carcinoma)
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Headache
- Depression and mood disorders
- Thrombocytopenia
- Neutropenia
- Thyroid dysfunction
- Injection site reactions
Key clinical trials
- VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B (PHASE2)
- Effect of Storytelling on Questionnaire Completion and Quality of Collected Data in an E-Cohort (NA)
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) (PHASE3)
- DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma (PHASE1, PHASE2)
- Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma (PHASE1)
- Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) (PHASE2)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C (PHASE3)
- Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pegylated Interferon alpha-2a CI brief — competitive landscape report
- Pegylated Interferon alpha-2a updates RSS · CI watch RSS
- ANRS, Emerging Infectious Diseases portfolio CI
Frequently asked questions about Pegylated Interferon alpha-2a
What is Pegylated Interferon alpha-2a?
How does Pegylated Interferon alpha-2a work?
What is Pegylated Interferon alpha-2a used for?
Who makes Pegylated Interferon alpha-2a?
Is Pegylated Interferon alpha-2a also known as anything else?
What drug class is Pegylated Interferon alpha-2a in?
What development phase is Pegylated Interferon alpha-2a in?
What are the side effects of Pegylated Interferon alpha-2a?
What does Pegylated Interferon alpha-2a target?
Related
- Drug class: All Interferon alpha drugs
- Target: All drugs targeting Interferon-alpha receptor (IFNAR)
- Manufacturer: ANRS, Emerging Infectious Diseases — full pipeline
- Therapeutic area: All drugs in Immunology, Virology, Oncology
- Indication: Drugs for Chronic hepatitis C
- Indication: Drugs for Chronic hepatitis B
- Indication: Drugs for Certain malignancies (melanoma, renal cell carcinoma)
- Also known as: Pegasys, Pegasys®, Roche, Peg-INF
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing